An-Najah National University

Publications of Waleed M. Sweileh,

Research Interests: 1.Clinical Renal Pharmacology and Therapeutics 2.Evidence Based Pharmacotherapy 3.Pharmacoepidemiology

  • Bookmark and Share Email
  • Wednesday, February 4, 2004
  • Pharmacology and Therapeutics of Anti-sense Oligodeoxynucleotides
  • Published at:Not Found
  • Pharmacology and Therapeutics of Anti-sense Oligodeoxynucleotides

    Waleed Sweileh

    College of Pharmacy, An-Najah National University, Nablus, Palestine

    E-mail: [email protected]

    Received: (18/9/2002), Accepted: (9/12/2003)


    The purpose of this review is to provide pharmacists and pharmacologists with a

    background information about current therapeutic potentials and clinical trials on the

    anti-sense oligonucleotides (AS oligos). Anti-sense oligonucleotides are short, modified

    single stranded DNA or RNA that hybridize with target mRNA and inhibit synthesis of

    encoded peptide. This inhibition is achieved by either degradation of target mRNA by

    RNase enzyme or by blocking translation. The specificity of hybridization makes antisense

    treatment an attractive strategy to selectively modulate the expression of genes

    involved in the pathogenesis of diseases. Anti-sense oligos have now reached phase I

    and II in clinical trials for the treatment of cancer and viral infections. One anti-sense

    drug has been approved for local treatment of retinitis induced by cytomegalovirus. A

    number of important challenges for the development of anti-sense oligonucleotides in

    the clinical use have been identified, including stability, cellular uptake, target

    sequence selection, oligonucleotide: protein interactions, and cost of manufacture.

  • Bookmark and Share Email
Leave a Comment


  • No Attachments Found for this Article


Waleed M. Sweileh, Professor of Clinical Pharmacology & Pharmacy:
Show Full ProfileEnglish CV


Please do not email me if you do not know me
Please do not e-mail me if you do not know me